These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 34859070)

  • 1. Sacubitril-Valsartan, Clinical Benefits and Related Mechanisms of Action in Heart Failure With Reduced Ejection Fraction. A Review.
    Pascual-Figal D; Bayés-Genis A; Beltrán-Troncoso P; Caravaca-Pérez P; Conde-Martel A; Crespo-Leiro MG; Delgado JF; Díez J; Formiga F; Manito N
    Front Cardiovasc Med; 2021; 8():754499. PubMed ID: 34859070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacubitril/Valsartan in Heart Failure Hospitalization: Two Pills a Day to Keep Hospitalizations Away?
    Sakhamuri N; Athiyaman S; Randhi B; Gutlapalli SD; Pu J; Zaidi MF; Patel M; Atluri LM; Gonzalez NA; Alfonso M
    Cureus; 2023 Apr; 15(4):e37335. PubMed ID: 37181979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual Angiotensin Receptor and Neprilysin Inhibition with Sacubitril/Valsartan in Chronic Systolic Heart Failure: Understanding the New PARADIGM.
    Lillyblad MP
    Ann Pharmacother; 2015 Nov; 49(11):1237-51. PubMed ID: 26175499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Outcomes with Sacubitril-Valsartan in Heart Failure: Emerging Clinical Data.
    Cuthbert JJ; Pellicori P; Clark AL
    Ther Clin Risk Manag; 2020; 16():715-726. PubMed ID: 32848403
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined Angiotensin Receptor Antagonism and Neprilysin Inhibition.
    Hubers SA; Brown NJ
    Circulation; 2016 Mar; 133(11):1115-24. PubMed ID: 26976916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Narrative review in the current role of angiotensin receptor-neprilysin inhibitors.
    Cruz Rodriguez JB; Cu C; Siddiqui T
    Ann Transl Med; 2021 Mar; 9(6):518. PubMed ID: 33850915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Gong J; Wang W; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; Desai AS; Shi VC; Lefkowitz MP; McMurray JJV
    JACC Heart Fail; 2017 Jul; 5(7):471-482. PubMed ID: 28662936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction.
    King JB; Shah RU; Bress AP; Nelson RE; Bellows BK
    JACC Heart Fail; 2016 May; 4(5):392-402. PubMed ID: 27039128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacubitril/Valsartan in Asian Patients with Heart Failure with Reduced Ejection Fraction.
    Dewan P; Docherty KF; McMurray JJV
    Korean Circ J; 2019 Jun; 49(6):469-484. PubMed ID: 31172710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential mechanisms of beneficial effect of sacubitril/valsartan on glycemic control.
    Seferovic JP; Solomon SD; Seely EW
    Ther Adv Endocrinol Metab; 2020; 11():2042018820970444. PubMed ID: 33489085
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changing the treatment of heart failure with reduced ejection fraction: clinical use of sacubitril-valsartan combination.
    Kaplinsky E
    J Geriatr Cardiol; 2016 Nov; 13(11):914-923. PubMed ID: 28133468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current evidence of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction.
    Abumayyaleh M; El-Battrawy I; Behnes M; Borggrefe M; Akin I
    Future Cardiol; 2020 Jul; 16(4):227-236. PubMed ID: 32186406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Switching Patients With Heart Failure and Reduced Ejection Fraction to Sacubitril/Valsartan: The Australian Perspective.
    Chin KL; Zomer E; Wang BH; Liew D
    Heart Lung Circ; 2020 Sep; 29(9):1310-1317. PubMed ID: 32303468
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.